1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1

Endocrinology

Volumn 138, Issue 4, 1997, Pages 1491-1497

  Blutt, Sarah E ^a   Allegretto, Elizabeth A ^b   Pike, J Wesley ^c   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CALCITRIOL; RETINOID X RECEPTOR; SEOCALCITOL;

ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030910440     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.138.4.5063     Document Type: Article

References (31)

1. Schwartz GG, Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307-1312
2. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
3. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
4. Giguere V 1994 Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 15:61-79
5. McDonnell DP, Mangelsdorf DJ, Pike WJ, Haussler MR, O'Malley BW 1987 Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 235:1214-1217
6. Schrader M, Bendik I, Becker-Andre M, Carlberg C 1993 Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268:17830-17836
7. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, Boehm MF, White SK, Pike JW, Heyman RA 1993 Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem 268:26625-26633
8. Fong C, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM 1993 Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 149:1190-1194
9. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE, Suto CM, Davies JA, Heyman RA, Nadzan AM 1995 Design and synthesis of potent retinoic X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38:3146-3155
10. Eager NS, Rowe A, Brickell PM 1991 A member of the chicken RXR family of nuclear receptors activates transcription in response to retinoic acid. FEBS Lett 292:103-106
11. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC 1992 EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273-2280
12. Titcomb MW, Gottardis MM, Pike JW, Allegretto EA 1994 Sensitive and specific detection of retinoid receptor subtype proteins in cultured cell and tumor extracts. Mol Endocrinol 8:870-877
13. Colston KW 1995 Vitamin D and breast cancer: the therapeutic potential of new vitamin D analogues. Endocr Relat Cancer 2:187-201
14. 3. Endocrinology 136:20-26
15. Colston KW, Chander SK, Mackay AG, Coomb RC 1992 Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702
16. 3 are differentially modified by 9-cis-retinoic acid. Cancer Res 56:623-632
17. Anderson JJB, Toverud SU 1994 Diet and vitamin D: a review with an emphasis on human function. J Nutr Biochem 5:58-65
18. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561
19. 3 receptor (VDR) homodimers into VDR-retinoid × receptor heterodimers. Mol Cell Biol 14:3329-3338
20. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W 1993 Two nuclear signalling pathways for vitamin D. Nature 361:657-660
21. 3 or its derivatives. J Biol Chem 269:2971-2978
22. Kephart DD, Walfish PG, Deluca H, Butt TR 1996 Retinoid × receptor isotope identity directs human vitamin D receptor heterodimer transactivation from the 24-hydroxylase vitamin D response elements in yeast. Mol Endocrinol 10:408-419
23. James SY, Mackay AG, Colston KW 1995 Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14:391-394
24. Peehl DM, Wong, ST, Cramer SD, Gross C, Feldman D 1995 Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D3 on prostatic epithelial cells. Urol Oncol 1:188-194
25. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P 1992 The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-520
26. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, Roberts AB, Sporn MB 1995 Chemopreventative activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 55:5621-5627
27. Elstner E, Linker-Israeli M, Said J, Umiel T, deVos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP 1995 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830
28. 3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 191:221-226
29. 3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 61:806-811
30. 3. Int J Oncol 8:41-47
31. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153